Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.

•Systemic estrogens induce a dose-dependent reduction in TC, LDL-C and Lp(a), as well as an increase in HDL-C concentrations.•Transdermal rather than oral estrogens should be used in women with hypertriglyceridemia.•With regard to progestogens, micronized progesterone or dydrogesterone is preferred, due to their neutral effect on lipid profile.•Menopausal hormone therapy is not recommended for the sole purpose of lipid profile improvement or cardiovascular disease risk reduction.•Dietary changes and pharmacological management should be tailored to the type of dyslipidemia (statins constitute the mainstay of treatment).